Peer-influenced content. Sources you trust. No registration required. This is HCN.
Medical Professionals Reference (MPR)
Mounjaro (tirzepatide) is a first-in-class, once-weekly, dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single molecule. It enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner. The FDA approval of Mounjaro as an adjunct therapy to diet and exercise for adults with type 2 diabetes was based on clinical trials where treatment with Mounjaro resulted in statistically significant reduction in both A1c and weight vs. semaglutide, insulin degludec, and insulin glargine.
Endocrinology, Diabetes, Metabolism May 24th 2022
MDLinx
Lilly Pharmaceutical’s Mounjaro (tirzepatide) is a once-weekly injection that promotes weight loss by mimicking the effects of incretins. This combination of a GLP-1 and a glucose-dependent insulinotropic polypeptide (GIP) yields weigh loss results comparable to surgical options.
Endocrinology, Diabetes, Metabolism May 17th 2022
Annals of Internal Medicine
Among adults aged 35 years or older with a body mass index (BMI) of 25 kg/m2, the prevalence of diabetes in Asian, Black, and Hispanic Americans was significantly higher than that in White Americans. Using screening thresholds specific to race and ethnicity has the potential to reduce disparities in diabetes diagnosis.
Medtelligence
The lipid metabolism plays an important role in the development of cardiovascular diseases and type 2 diabetes. However, little has been known about the molecular relationships. But now, a set of lipids have been statistically associated with cardiovascular disease and type 2 diabetes.
Cardiology May 3rd 2022
Cleveland Clinic Journal of Medicine
Hyperglycemia is associated with poor clinical outcomes in critically ill patients. Most medical societies recommend less stringent glucose control, in the range of 140 to 180 mg/dL, for critically ill patients. In this population, although glucose management is essential, hypoglycemia is associated with increased mortality. Enhancing the amount of time glucose levels are in the target range and minimizing glycemic variability have been associated with improved outcomes in critically ill patients.
Endocrinology, Diabetes, Metabolism April 27th 2022
Diabetes medications, such as metformin, have glucose-independent effects on the male reproductive system. However, until now, it was unknown if these effects lead to birth defects in offspring. This study concludes that metformin intake in men is associated with major birth defects, particularly genital birth defects in boys.
Endocrinology, Diabetes, Metabolism April 5th 2022